Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
Cholecalciferol; Calcium carbonate
Laboratoire Innotech International
A12AX
Cholecalciferol; Calcium carbonate
500 mg/400 international unit(s)
Chewable tablet
Product not subject to medical prescription
Calcium, combinations with vitamin D and/or other drugs
Marketed
1996-01-08
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT IDÉOS 500MG/400 IU CHEWABLE TABLETS CALCIUM / VITAMIN D READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse. WHAT IS IN THIS LEAFLET 1. What IDEOS is and what it is used for 2. What you need to know before you take IDEOS 3. How to take IDEOS 4. Possible side effects 5. How to store IDEOS 6. Contents of the pack and other information 1. WHAT IDEOS IS AND WHAT IT IS USED FOR This medicine provides calcium and vitamin D3 (also called cholecalciferol) to the body. This medicine is used: in case of vitamin D and calcium deficiency in the elderly. in association with some treatments of osteoporosis (a condition where bone mass decreases and bone brittleness increases), when there is deficiency or a risk of deficiency in vitamin D and calcium. This medicine is intended for use in adults. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE IDEOS DO NOT TAKE IDEOS: - If you are allergic (hypersensitive) to calcium or vitamin D or any of the other ingredients of this medicine (listed in section 6). - if you are allergic (hypersensitive) to peanut or soya (this product contains soybean oil), - if you have high calcium levels in your blood (hypercalcaemia), - If you have high levels of calcium in your urine (hypercalciuria), - If you have a condition that leads to hypercalcaemia and/or hypercalciuria (e.g. overactive parathyroid glands, a disease of the bone marrow, a malignant bone tumor, bone metastases), - If you are suffering from kidney disease (kidney failure), - If Lees het volledige document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT IDEOS 500mg/400 IU Chewable Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENTS PER TABLET: Calcium carbonate ......................................................... 1250 mg (equivalent to 500 mg of elemental calcium) Cholecalciferol (vitamin D 3 ) ............................................. 400 IU (equivalent to 10 µg) Excipients with known effects: 475mg sorbitol, 1.52mg sucrose, 0.3mg hydrogenated soya bean oil. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Chewable tablets. Greyish white, square, tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS -Vitamin D and calcium deficiency correction in the elderly. -Vitamin D and calcium supplementation as an adjunct to specific therapy for osteoporosis in patients with established, or at high risk of vitamin D and calcium combined deficiencies. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For adults only. Oral use. Chew or suck the tablets. One tablet, twice a day. 4.3 CONTRAINDICATIONS -Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. -Hypercalcaemia, as a result of hyperparathyroidism (primary or secondary), hypercalciuria, calcium lithiasis, tissue calcifications (nephrocalcinosis) -Vitamin D overdose -Myeloma and bone metastases -Renal insufficiency (creatinine clearance < 20 ml/min) -This product contains partially hydrogenated soybean oil. Patients should not take this medicinal product if they are allergic to peanut or soya. Idéos tablets are also contra-indicated in patients where prolonged immobilisation is accompanied by hypercalcaemia and/or hypercalciuria. In these cases, treatment should only be resumed when the patient becomes mobile. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Lees het volledige document